Found 25 clinical trials
Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
The primary objective of the study is to evaluate the efficacy of tislelizumab in participants with relapsed/refractory classical Hodgkin lymphoma, as measured by the overall response rate per
- 0 views
- 22 Dec, 2021
- 45 locations
Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
The primary objective of this study is to evaluate the efficacy of tislelizumab in participants with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by Progression-free
- 0 views
- 12 Jan, 2022
- 8 locations
Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
Survival (PFS) in participants with relapsed or refractory Classical Hodgkin Lymphoma compared to treatment with Chemotherapy.
- 0 views
- 15 Feb, 2021
- 1 location
Itacitinib + Everolimus in Hodgkin Lymphoma
This is an open-label, single-group, Phase I/II study of itacitinib in combination with everolimus in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL).
- 1 views
- 06 Aug, 2021
- 1 location
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant
A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin's Lymphoma, Followed by
- 0 views
- 27 Jan, 2021
- 19 locations
Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
The aim of the trial is to improve disease control after an allogeneic stem cell transplantation (alloSCT) for relapsed or refractory classical Hodgkin lymphoma (rrHL, cHL) with consolidation
- 0 views
- 26 Jan, 2021
- 1 location
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
The primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in participants treated with pembrolizumab Q6W.
- 0 views
- 19 Jan, 2022
- 22 locations
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
- 39 views
- 25 Aug, 2021
- 4 locations
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL
This study is looking at the effects of Ipilimumab when it is given alone or in combination with Nivolumab to patients with relapsed or refractory classic Hodgkin's lymphoma (cHL). The names of the study drugs involved in this study are: Ipilimumab Nivolumab
- 0 views
- 03 Oct, 2021
- 3 locations
Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
This phase II trial studies how well umbralisib and pembrolizumab work in treating patients with classical Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Umbralisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with …
- 0 views
- 04 Sep, 2021
- 1 location